The post suggests that the Trump administration is actively working to streamline the process of expanding manufacturing in the US, which could lead to increased investment and job creation in the pharmaceutical industry. This could have a positive impact on the stock prices of US-based pharmaceutical companies, such as Eli Lilly. Historically, Trump's statements of support for specific industries have led to increased market confidence and a subsequent boost in stock prices. Additionally, the mention of an executive order streamlining the process could lead to reduced regulatory barriers, making it easier for pharmaceutical companies to operate and expand in the US. However, it's worth noting that the impact of this post may be limited to the pharmaceutical industry, and the broader market may not be significantly affected.